Last reviewed · How we verify
Maintenance of Healing Gastric Ulcer — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zantac | ranitidine | GSK (originally Glaxo) | H2 receptor antagonist | Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor | 1983-06-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GSK (originally Glaxo) · 1 drug in Maintenance of Healing Gastric Ulcer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Maintenance of Healing Gastric Ulcer:
- Maintenance of Healing Gastric Ulcer treatment updates — RSS
- Maintenance of Healing Gastric Ulcer treatment updates — Atom
- Maintenance of Healing Gastric Ulcer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Maintenance of Healing Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-of-healing-gastric-ulcer. Accessed 2026-06-10.
Related
- Maintenance of Healing Gastric Ulcer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing